Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001599298-26-000039
Filing Date
2026-04-30
Accepted
2026-04-30 17:00:54
Documents
60
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q smmt-20260331.htm   iXBRL 10-Q 754092
2 EX-31.1 ex311dugganq12026.htm EX-31.1 11695
3 EX-31.2 ex312zanganehq12026.htm EX-31.2 11740
4 EX-31.3 ex313soniq12026.htm EX-31.3 11790
5 EX-32.1 ex321q12026.htm EX-32.1 10970
11 GRAPHIC smmt-20260331_g1.jpg GRAPHIC 18976
12 GRAPHIC smmt-20260331_g2.jpg GRAPHIC 58830
  Complete submission text file 0001599298-26-000039.txt   4786873

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT smmt-20260331.xsd EX-101.SCH 36412
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT smmt-20260331_cal.xml EX-101.CAL 43808
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT smmt-20260331_def.xml EX-101.DEF 153076
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT smmt-20260331_lab.xml EX-101.LAB 508617
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT smmt-20260331_pre.xml EX-101.PRE 331796
64 EXTRACTED XBRL INSTANCE DOCUMENT smmt-20260331_htm.xml XML 473603
Mailing Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131
Business Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131 305-203-2034
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

EIN.: 371979717 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36866 | Film No.: 26926916
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)